(Speaker Term: July 1, 2014 - June 30, 2016)
Dimitrios P. Kontoyiannis, M.D., Sc.D. (term: 7/1/14 through 6/30/16)
Frances King Black Endowed Professor
The University of Texas MD Anderson Cancer Center
1400 Pressler Street FCT12.5069, Unit 1463
Houston, TX 77030-3772
Speaker’s Website: http://faculty.mdanderson.org/Dimitrios_Kontoyiannis/Default.asp
ASM MEMBERSHIP AFFILIATION – Dimitrios P. Kontoyiannis, M.D., Sc.D.
Primary Division: F (Medical Mycology)
Secondary Division: A (Antimicrobial Chemotherapy)
LECTURE TOPICS AND DESCRIPTIONS – Dimitrios P. Kontoyiannis, M.D., Sc.D.
Future Directions of Mycology Research in the 21st Century
This lecture gives a conceptual framework on the unmet needs in the study of fungal disease in regards to epidemiology, risk factors, pathogenesis, diagnosis, management and education.
Antifungal Combination Therapy for Aspergillus and Other Molds
This lecture reviews the preclinical and clinical evidence and controversies in the complex field of antifungal combinations against opportunistic molds.
Mucormycosis in 2014: An Update
This is a state of the art lecture on new developments in the study of mucormycosis in the lab and in the clinic.
Non-vertebrate Models in Experimental Mycology
This lecture reviews the studies using non-vertebrate hosts, focusing on the Lecturer’s work using Drosophila, to study fungal pathogenesis and antifungal drug action.
Principles for the Management of Opportunistic Mycoses in Patients with Hematologic Cancer
BIOGRAPHICAL SKETCH – Dimitrios P. Kontoyiannis, M.D., Sc.D.
Dr. Dimitrios P. Kontoyiannis received his medical degree Summa Cum Laude from the National and Kapodistrian University of Athens in Greece. He then did a post-doctoral research fellowship in Infectious Diseases at The University of Texas MD Anderson Cancer Center in Houston, TX, followed by training in Internal Medicine at Baylor College of Medicine in Houston, TX, where he served as a Chief Resident. He was subsequently trained as a clinical fellow in Infectious Diseases at Massachusetts General Hospital and obtained a Master in Clinical Sciences from Harvard Medical School in Boston. He spent 3 years at the Whitehead Institute for Biomedical Sciences as a fellow in the Harvard/MIT Clinical Investigators Training Program. He is currently the Frances King Black Endowed Professor and Deputy Head-Research in the Division of Internal Medicine at The University of Texas MD Anderson Cancer Center and adjunct professor at Baylor College of Medicine and University of Houston. His research work is in the area of experimental and clinical mycology, focusing on traditional (mouse) and mini-host (Drosophila) models of infection, antifungal drug resistance, pathogenesis, pharmacology and various aspects of epidemiology, diagnostics and treatment of fungal infections. He is the recipient of several national and institutional awards, has authored over 400 peer-reviewed manuscripts and has been invited to give over 100 lectures in international conferences and prestigious institutions in the United States and abroad.
CV is available by request from firstname.lastname@example.org at ASM Headquarters
LECTURER’S PERSONAL STATEMENT – Dimitrios P. Kontoyiannis, M.D., Sc.D.
I have worked to develop a comprehensive multi-disciplinary program in experimental and clinical mycology. This program has both translational and clinical components, and has achieved national and international recognition as well as institutional awards. Our research program has been described as prolific and innovative by peers at other institutions. As a big proponent of quality team work, we have established several successful collaborations both within and outside the institution. Several milestones of my research career include the establishment of the Drosophila melanogaster as a novel and promising model to study fungal pathogenesis and treatment, the first description of the fungal exotoxin gliotoxin in angiogenesis, the synergy of calcineurin and ergosterol pathway inhibition against molds, the development of subacute experimental models of aspergillosis, the insight regarding the paradoxical effect of the fungal cell wall inhibiting agents against fungi, the introduction of peptidomimetic approaches to treatment and diagnosis in experimental systems, the description of apoptosis in Mucorales, the introduction of the concept of sequential antifungal exposure in in vitro and virulence testing, the immunomodulatory activity of the echinocandins, and several others. We have published extensively in prestigious specialty journals (Clinical Infectious Diseases, Antimicrobial Agents and Chemotherapy, J Antimicrobial Chemotherapy, J Infectious Diseases, Eukaryotic Cell, J Clinical Microbiology, PLOS Pathogens) and oncology/hematology-related and general journals (PNAS, Blood, PLOS One, J Immunology, Annals of Internal Medicine, American J of Medicine, Lancet, JAMA, NEJM, Cancer, J Clin Oncology, J Immunology). Several of our papers were highlighted in the Faculty of 1000 Medicine database (http://f1000.com/). I have also led the pivotal surveillance program of fungal infections in stem cell transplant population coordinated by the Centers for Disease Control (TRANSNET) and served on several steering committees for clinical protocol development. My H index is 60 and I have in my bibliography approximately 400 publications with over 13,000 citations.